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A B S T R AC T
Background: Immunoglobulin G4-related disease (IgG4-RD) 
is a systemic fibro-inflammatory condition with involvement 
of different organs. The pathophysiological mechanism is 
unclear, but fibrosis is the hallmark of this disease. Early 
recognition is critical to avoid irreversible organ damage. 
Recently improved histological testing boosts the diagnostic 
yield. We present three cases of patients with IgG4-RD to 
emphasise the broad clinical presentation of this disease. 
Case descriptions: Patient A, a 63-year-old male with bilateral 
orbital swelling due to IgG4-RD, was shown to suffer from 
IgG4-RD in a multifocal pattern as demonstrated by PET 
scanning. Patient B, a 53-year-old male with a long-standing 
abdominal mass of unknown origin, eventually proved 
to have IgG4-RD. Patient C was a 32-year-old male 
admitted with pleural effusion and pericardial tamponade. 
Histological diagnosis after pericardiectomy confirmed 
IgG4-RD. 
Discussion: IgG4-RD has many faces and may mimic other 
conditions, such as malignancy and infectious diseases. 
Knowledge of this disease is needed to avoid unnecessary 
diagnostics and delay in treatment. IgG4-RD may be 
suspected based on specific clinical findings such as elevated 
serum IgG4 levels, but the diagnosis can only be established 
histologically. Although corticosteroids are an effective 
first choice of therapy, the relapse rate after this treatment 
remains high. The role of disease-modifying antirheumatic 
drugs in the treatment of IgG4-RD has not been outlined yet, 
but there is increasing evidence that rituximab might be an 
effective second-line therapy. 
Conclusion: IgG4-RD is a disease with many faces requiring 
early recognition and therapy to avoid permanent damage of 
the organs.
K E Y WOR DS
Fibro-inflammatory disease, immunoglobulin G4, and 
IgG4-related disease
I N T RODUC T I ON
Immunoglobulin G4-related disease (IgG4-RD) is a 
systemic fibro-inflammatory condition with manifestations 
in almost all parts of the human body.1 It is characterised 
by tumour-like infiltration of IgG4-positive plasma 
cells in the tissues, mostly with fibrotic or sclerotic 
abnormalities, and often elevated serum IgG4 levels.1 
IgG4-RD was initially described in patients with sclerosing 
pancreatitis, but from 2003 it is recognised as a systemic 
disease.2 The disease can manifest in one single organ, 
but it can also occur simultaneously in multiple organs. 
IgG4-RD usually occurs in the salivary and lacrimal 
glands, the orbit, pancreas and lymph nodes. Other 
preferential localisations include the lungs, kidneys, 
thyroid, peritoneum and prostate.3 Conditions previously 
called Mikulicz’s disease, sclerosing sialadenitis, 
inflammatory orbital pseudotumour, a subset of idiopathic 
retroperitoneal fibrosis and Riedel’s thyroiditis are now 
reclassified under the umbrella of IgG4-RD.4 IgG4-RD 
mimics many infectious, inflammatory and malignant 
disorders often leading to a delay in both diagnosis 
and treatment, potentially progressing into irreversible 
fibrosis.5 Awareness of this disease is important to avoid 
unnecessary delay. We therefore present three different 
cases of patients with IgG4-RD to emphasise the broad 
clinical presentation of this disease and present a review 
on the pathogenesis, diagnosis and treatment. 
C A SE  P R E S E N TAT I ONS
We briefly present three different cases of IgG4-RD. The 
patient characteristics and the main clinical features are 
shown in table 1. 
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Table 1. Characteristics and the main clinical features of the patients
Patient A Patient B Patient C
Gender Male Male Male
Age 63 years 53 years 32 years
Medical 
history
- Suspected pulmonary sarcoidosis 
without histological confirmation 
20 years ago – Hypothyroidism 
- Lower urinary tract symptoms – 
No asthma or allergies 
- Unknown abdominal mass for 
the past 20 years – No asthma or 
allergies
- Unremarkable – No asthma or 
allergies
Symptoms 
and duration 
of symptoms
Progressive bilateral painless 
periorbital swelling and diplopia for 
4 months
Episodes of malaise, weight loss and 
an abdominal mass of unknown 
origin for the last 20 years
Malaise, dyspnoea, pleural and 
pericardial effusion for a couple 
of weeks. Four weeks after 
presentation pericardiectomy was 
performed. Afterwards, persistent 
pleural effusion in 3-month follow-
up, for which prednisone was 
started
Diagnosis Orbital IgG4-RD with multifocal 
disease manifestation on PET imaging
Mesenteric IgG4-RD Pericardial and pleural IgG4-RD
Serum IgG4 
pre-treatment
1.65 g/l 25 g/l 5.5 g/l (after pericardiectomy)
Serum IgG4 
after initiating 
treatment
0.28 g/l: after prednisone 1 mg/kg/
day. This value was measured 14 
weeks after starting prednisone. 
Prednisone was then tapered to 
20 mg/day from initial doses of 
60 mg 
4.58 g/l: after prednisone 1 mg/kg/
day. This value was measured 10 
weeks after starting prednisone. 
Prednisone was then tapered to 
25 mg/day from initial doses of 
60 mg. Azathioprine was started 
2 months after initiating prednisone 
1.69 g/l: after pericardiectomy and 
prednisone 30 mg/day. This value 
was measured 7 weeks after starting 
prednisone, prednisone was tapered 
to 20 mg/day from initial doses of 
30 mg
ANA Negative Negative Negative
Other relevant 
findings 
ESR and CRP normal. ACE normal.
Anti-TSH receptor absent
Elevated ESR and CRP, decreasing 
with therapy. Microcytic anaemia 
responding very well to iron 
supplements. Gastroscopy, 
colonoscopy and bone marrow 
survey normal
Elevated CRP normalising after 
pericardiectomy. ESR not measured.
ANCA, rheumatic factors, lupus 
anticoagulants absent, complement 
factors normal
Imaging - MRI brain: bilateral enlarged and 
contrast-enhancing lacrimal glands;
- PET scan: multifocal increased 
activity in various organs, including 
the lacrimal glands, parotid 
gland, thyroid, prostate, right 
seminal vesicle, testis and multiple 
mediastinal and hilar lymph nodes
CT abdomen: mesenteric mass, 
decreasing in volume after 
treatment
- CT thorax and abdomen: pleural 
and pericardial effusion;
- X-thorax: bilateral pleural effusion 
on both sides, vanishing after 
starting prednisone;
- PET: slight activity of the pleura 
without other abnormalities (after 
pericardiectomy)
Histology Surgical excision of lacrimal gland:
- Lymphoplasmacytic infiltration, 
storiform fibrosis, obliterative 
phlebitis, >200 IgG4 positive 
plasma cells per HPF and IgG4/IgG 
ratio >0.5
Fine needle biopsy mesenteric mass:
Lymphoplasmacytic infiltration, 
storiform fibrosis, >50 IgG4 positive 
plasma cells per HPF and IgG4/IgG 
ratio >0.5. No obliterative phlebitis
Pericardiectomy:
Lymphoplasmacytic infiltration, 
storiform fibrosis, obliterative 
phlebitis, >100 IgG4 positive 
plasma cells per HPF and IgG4/IgG 
ratio >0.7
Treatment Prednisone 1 mg/kg, currently 
being tapered successfully. No 
maintenance therapy initiated, 
because of normalisation of 
symptoms, serum IgG4 and MRI
Prednisone 1 mg/kg and 
azathioprine 150 mg/day after 
tapering prednisone. Azathioprine 
was initiated because ESR and 
serum IgG4 were not normalised 
and persistence of abdominal mass 
Prednisone 30 mg daily, currently 
being tapered successfully. No 
maintenance therapy was initiated, 
because serum IgG4 almost 
normalised and pleural effusion 
disappeared
CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; ACE = angiotensin-converting enzyme; TSH = thyroid-stimulating hormone;  
ANCA = anti-neutrophil cytoplasmic antibodies; ANA = antinuclear antibodies; HPF = high power field.
112
MA R CH  2 0 1 6 ,  V O L .  7 4 ,  N O  3
The Netherlands Journal of Medicine
Karim et al. Immunoglobulin G4-related disease.
Patient A 
This 63-year-old male patient was referred to the 
ophthalmologist because of a painless bilateral periorbital 
swelling and diplopia suspected to be lymphoma or 
recurrence of sarcoidosis. Pulmonary sarcoidosis was 
diagnosed on the basis of the clinical symptoms and was 
not histologically confirmed, and this had been stable 
without medication for 20 years. His history also included 
levothyroxine for hypothyroidism and alpha-blockers 
for relapsing lower urinary tract symptoms. Bilateral 
periorbital swelling with slight proptosis was found on 
physical examination. Laboratory tests revealed elevated 
serum IgG4 without other abnormalities. Computed 
tomography (CT) of the thorax and abdomen was normal. 
MRI of the brain revealed only bilateral enlarged and 
contrast-enhancing lacrimal glands (figure 1A). On F-18 
FDG PET/CT scan, multifocal increased activity was noted 
in various organs (table 1). Histology of the lacrimal gland 
was compatible with IgG4-RD (figure 1C+D). Prednisone 
1 mg/kg/day significantly decreased the periorbital 
swelling, but also resulted in a complete recovery of the 
urinary tract symptoms within one week and recovery of 
thyroid dysfunction. After four weeks, the steroids could 
be tapered and levothyroxine was discontinued without 
recurrence after six months of follow-up. 
Patient B 
A 53-year-old male patient consulted several medical 
specialists over the past 20 years because of an abdominal 
mass. Extensive diagnostics including biopsies and bone 
marrow examination did not yield any diagnosis. The 
patient complained of slowly progressive malaise, weight 
loss and abdominal pain. After referral to our hospital, 
IgG4-RD was suspected, also because of the elevated 
serum IgG4 levels. Laboratory tests further revealed an 
elevated erythrocyte sedimentation rate (ESR), normal 
ferritin and microcytic anaemia, known to have existed 
for years. Gastroscopy and colonoscopy were without 
evidence of malignancy, intraepithelial lymphocytosis, 
IgG4-RD, villous atrophy, Giardia, Whipple’s disease or 
Helicobacter pylori infection. CT imaging demonstrated 
a progressively increasing mesenteric mass of 50 mm 
surrounded by mesenteric lymphadenopathy (figure 2A). 
Histology of the mesenteric mass confirmed the diagnosis 
of IgG4-RD (figure 2C). Prednisone 1 mg/kg/day was 
initiated. Hereafter, the symptoms eased, the serum 
IgG4 and ESR decreased and haemoglobin levels almost 
normalised. The abdominal mass and lymphadenopathy 
decreased (figure 2B) and serum IgG4 and ESR levels 
showed a downward trend. The steroids were tapered after 
four weeks and azathioprine 150 mg daily was started after 
two months since the mass had not totally regressed. 
Patient C 
This 32-year-old male patient was admitted to the department 
of cardiology because of cardiac tamponade. On a CT of the 
thorax and abdomen both pleural and pericardial effusions 
were seen (figure 3A). Laboratory tests showed elevated 
C-reactive protein (CRP), ESR was not measured at that 
moment. Because of persistent pericardial effusion with 
constrictive signs, a pericardiectomy was performed and 
diuretics were given. Hereafter, the CRP normalised and 
the ESR was normal. Detailed bacteriological and virological 
analyses (including serology or viral load determinations 
of HIV, hepatitis A/B/C, Borrelia burgdorferi, syphilis, 
mycoplasma, tuberculosis, parvovirus, Cytomegalovirus, 
Epstein-Barr, Coxiella burnetii, toxoplasmosis, Coxsackie 
virus and varicella- zoster) were unremarkable. Elevated 
Figure 1. A+B: Transverse spin echo T1 weighted MRI of the orbit. A: Note the bilateral homogeneous enhancement 
of the enlarged lacrimal glands (yellow arrows). B: Normalisation of the size of the lacrimal gland and a dramatic 
decrease in enhancement after treatment with prednisone. C+D: Histology of the lacrimal gland of patient A. C: 
HE staining demonstrating lymphocytes, plasma cells and local fibrosis. Obliterative phlebitis was also observed. D: 
Immunohistochemical staining for IgG4 (brown colour) of the lacrimal gland of patient A showing widely scattered 
IgG4 positive plasma cells with an average of 240 per HPF out of 2 HPF with a ratio of 0.5 to total IgG plasma cells 
in the tissue. Figure C and D are at x200 magnification. MRI = magnetic resonance imaging; HE = haematoxylin 
and eosin; HPF = high-power field
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serum IgG4 and pericardial histology finally offered 
sufficient evidence for IgG4-RD (figure 3D+E). Cultures of 
the pericardial tissue ruled out bacterial pathogens including 
Mycobacterium tuberculosis. F-18 FDG PET/CT three months 
after pericardiectomy revealed slight activity of the pleura 
without other abnormalities. Prednisone 30 mg daily led 
to the disappearance of the pleural effusion (figure 3B+C) 
and almost normalisation of serum IgG4; diuretics were 
no longer required. Hereafter, the prednisone carefully was 
tapered to 20 mg in seven weeks without signs of recurrence.
Figure 2. A+B: CT image of the abdomen after intravenous contrast injection, venous phase. A: Pre-treatment: 
abdominal/mesenteric mass of 50 mm (red arrow) with enlarged mesenteric lymph nodes. B: Post-treatment: 
decrease in size of the mesenteric mass to 36 mm (blue arrow) and decrease in lymph nodes size. C: 
Immunohistochemical staining for IgG4 of mesenteric mass of patient B revealing widely scattered IgG4 plasma 
cells with an average of 421 per HPF out of 3 HPF with a ratio of 0.5 to total IgG plasma cells in the tumorous 
tissue. Unfortunately, no HE images were available, but lymphoplasmacytic infiltration and storiform fibrosis were 
seen and documented. Figure C is at x200 magnification
Figure 3 A: CT scan of the thorax showing bilateral pleural effusion (red arrows) and pericardial effusion (yellow 
arrow). B: Pleural effusion was evident on plain film of the thorax as well. C: Disappearance of pleural effusion 
six weeks after starting prednisone. D: Histology of pericardium of patient C. HE-staining showing lymphocytes, 
plasma cells and fibrosis. Obliterative phlebitis was also observed. E: Immunohistochemical staining for IgG4 
consists of IgG4 plasma cells with an average of 136 per HPF out of 3 HPF with a ratio of 0.7 tot total IgG plasma 
cells in the tissue. Figures D and E are at x200 magnification
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D I S CUS S I ON
Here we present three cases of patients with unrecognised 
IgG4-RD, each presenting with a different clinical 
presentation. The courses of these patients reflect the broad 
spectrum of clinical faces of IgG4-RD. By demonstrating 
the variable presentation of Ig4-RD, we briefly provide 
an overview of the spectrum of symptoms and treatment 
options in this new disease entity. 
IgG4-RD is a systemic disease that can be found in almost 
any organ, but with certain sites of preference (orbit, 
salivary tract, pancreas and lymph nodes) which may 
be guiding when considering this new disease entity. 
On the other hand, IgG4-RD mimics various benign 
and malignant disorders. Therefore, careful diagnostics 
should be applied before setting the diagnosis.1 The vast 
clinical manifestation range and potentially organ- and 
life-threatening situations emphasise that awareness of 
this relatively new entity is pivotal to swiftly set a diagnosis 
and prevent organ damage.3 This is highlighted by the 
histories of the presented patients. Patient A presented 
with a relatively short history, and lymphoma or recurrent 
sarcoidosis were suspected. Extensive diagnostics were 
conducted to rule out these entities. A typical FDG-uptake 
pattern led to the diagnosis of IgG4-RD by histology 
of a lacrimal gland. The abdominal mass resembling 
retroperitoneal fibrosis seen in patient B is remarkable and 
has rarely been described before.6 Multiple diagnostics 
including biopsies of the abdominal mass excluded 
conditions such as malignancy and infectious diseases. 
Eventually, after almost 20 years, attention towards 
IgG4 resulted in the diagnosis of IgG4-RD. Cardiac 
manifestations of IgG4-RD, such as in patient C, are 
rare.7 The patient presented with constrictive pericarditis 
and a pleural effusion. It remains a challenge to rule out 
infectious or malignant disease and consider IgG4-RD. 
The diagnosis of IgG4-RD is based on the combination of 
clinical presentation, serological and histological findings, 
but histology is the gold standard. Although the disease is 
called IgG4-RD, about 30 to 50% of histologically proven 
cases show normal IgG4 levels leading to misinterpretation 
and erroneous rejection of the diagnosis.7 Furthermore, 
the specificity and positive predictive value of serum IgG4 
concentrations are low, which make them poor disease 
markers. In our cases, serum IgG4 levels were elevated in 
all three patients, but with different ranges (1.65 to 25 g/l). 
Other, though unspecific, serological findings are ESR and 
CRP in patients with active disease, but these are elevated 
in 53% and 40%, respectively, of the cases.7 In this study 
51% of these patients had elevated serum IgG4.7 In our 
patients, not all elevated IgG4 levels corresponded with an 
elevated ESR and CRP. 
Only in patient A were the ESR and CRP both normal. 
Although speculative, longstanding active disease and 
high serum IgG could lead to elevated ESR and CRP, which 
applied in case B. 
Measuring plasmablasts originating from CD20+ 
B cells is a superior alternative to measuring IgG4 
concentrations in serum,8 but so far this technique has 
not been widely introduced for clinical application. So 
far, imaging studies play a crucial role in the diagnostics 
of IgG4-RD; however, imaging is not specific for this 
disease and several conditions such as malignancy should 
be excluded. Radionuclide imaging in patient A was 
more sensitive than conventional CT. Several studies 
have shown the usefulness of FDG-PET/CT scanning for 
diagnosis, staging and the degree of organ involvement and 
monitoring of therapy response, and this imaging method 
seems to detect more lesions than conventional methods 
such as ultrasonography and CT.9 This emphasises 
the utility of PET scanning in IgG4-RD. However, 
histology remains crucial for the diagnosis of IgG4-RD. 
The histological abnormalities should meet the Boston 
consensus on IgG4-RD.10 The characteristic histological 
features of IgG4-RD are dense lymphoplasmacytic 
infiltrate, storiform fibrosis and obliterative phlebitis. The 
ratio of IgG4/IgG-positive plasma cells in tissues should 
be greater than 0.4 and the numbers of IgG4-positive 
plasma cells per high power field should be greater than 
the numbers agreed in the consensus.10 The absolute 
numbers of IgG4-positive plasma cells and the thresholds 
for disease differ for the diverse organs. Our patients had 
histologically confirmed IgG4-RD according to the criteria; 
however, in case B no obliterative phlebitis was seen.
The pathogenesis of IgG4-RD is unclear.11 Generally, 
the disease is characterised by a decreased T-helper 
cells 1/T-helper cells 2 ratio and increased numbers of 
regulatory T-cells, most probably as a result from a certain 
antigen triggering the immune system. Production of 
different cytokines such as interleukin (IL)-4, IL-5, IL-10, 
IL-13 and transforming growth factor (TGF)-beta leads to 
co-activations of B-cells, production of IgG4 expressing 
B-cells and fibrosis. Still, the role of IgG4 antibodies is 
unclear, but in the pathophysiology of IgG4-RD these 
antibodies most probably play an anti-inflammatory role 
as response to an unknown trigger.12 Patient C presented 
with constrictive pericarditis and pleural effusion. Plasma 
cell manifestation of the pericardium has also been 
described in multiple myeloma,13 whereby infiltration of 
plasma cells in the pericardium is suggested to be the 
reason. Maybe some viral infection led to IgG4-positive 
plasma cell infiltration in the serosal cavity leading to the 
clinical manifestation of this disease, but this remains 
a speculative hypothesis. The pleural effusion was most 
probably also because of infiltration by lymphoplasmacytic 
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cells, as it was slightly positive on PET and disappeared 
after starting prednisone. However, secondary pleural 
effusion because of restricted heart function due to 
constrictive pericarditis could also have contributed to the 
development of pleural effusion.
IgG4-RD can cause significant morbidity and even lead 
to organ damage. Aggressive treatment is therefore 
necessary, especially when vital organs are at risk.11 
Glucocorticoids are the first choice of treatment for most 
types of IgG4-RD and are mostly effective at a prednisone 
dosage of 30-40 mg/day and should be adjusted according 
to body weight or in cases of aggressive disease.14 This 
treatment dose is, in most cases, rapidly effective, but 
should be maintained for two to four weeks after initiation. 
Thereafter, prednisone can be tapered according to 
clinical responses. The clinical response of prednisone 
is dependent upon the organ system involved and the 
degree of fibrosis. Pancreatic function and lacrimal gland 
function, for example, will respond better to this treatment 
than retroperitoneal disease or sclerosing mesenteritis.14 
This phenomenon highlights the need for earlier treatment 
of this disease.5 About 25% of patients demonstrate relapse 
after tapering prednisone necessitating steroid-sparing 
agents. Patient A responded very well to prednisone. His 
symptoms, serum IgG4 and MRI imaging normalised and 
remained so during tapering. Patient C also responded 
very well to prednisone. His symptoms disappeared, serum 
IgG4 reached almost normal levels and a recent chest X-ray 
no longer demonstrated pleural effusion. Therefore, we 
decided not to initiate maintenance therapy in cases A and 
C. According to international consensus, a steroid-sparing 
agent is appropriate when the glucocorticoid dosage cannot 
be tapered due to persistently active disease.14 For this 
reason, azathioprine was initiated in case B. Conventional 
steroid-sparing agents such as mycophenolate mofetil, 
azathioprine and methotrexate have all been used in 
the treatment of IgG4-RD, but management of further 
immunosuppressive therapy with these disease-modifying 
antirheumatic drugs (DMARDs) has not been outlined14 
and there are no studies confirming the superiority of 
one of these agents in the treatment of IgG4-RD. There 
is improving evidence for the efficacy of rituximab in the 
treatment of IgG4-RD, even as a single therapy.15 This 
B-cell ablative therapeutic agent has induced clinical 
remission in patients with various organ involvement of 
IgG4-RD.3 More case series or prospective studies with 
different DMARDs and rituximab are required in order 
to define the (long-term) effect of these agents in the 
treatment of IgG4-RD. 
CONC LUS I ON
In conclusion, IgG4-RD is a rare and new clinical entity 
with many faces and manifestations in different parts of 
the body. Early recognition is critical to start treatment and 
to avoid permanent damage of the organs. Diagnosis is 
based on histology, while serum IgG4 could be supportive. 
Glucocorticoids are the first choice of treatment, but there 
is often a need for maintenance therapy. Several DMARDs 
as well as rituximab are used in the treatment of IgG4-RD, 
with growing evidence for the latter.
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